Activation of PPAR-γ reduces insulin resistance by increasing adiponectin levels [71]; adiponectin, in turn, reduces lipid accumulation in the liver and further contributes to the anti-inflammatory effects of PPAR-γ by enhancing PPAR-α activity and fatty acid oxidation [72–74]. Here, ADIPOQ is linked to Insulin resistance.